T2DM: Type 2 diabetes mellitus; CV: Cardiovascular; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; HHF: Hospitalization due to heart failure; MI: Myocardial infarction; MACE: Major adverse cardiac effects; CAD: Coronary artery disease; CKD: Chronic kidney disease; CVD: Cardiovascular disease; AF: Atrial fibrillation. Here, SLC5A2 is linked to coronary artery disorder.